a moderate CYP3A4 inhibitor and buprenorphine is a CYP3A4 substrate.
Buspirone: (Moderate) Use caution if coadministration of ribociclib with buspirone is necessary, as the systemic exposure of buspirone may be increased resulting in an increase in buspirone-related adverse reactions. Consider starting with a low dose of buspirone with subsequent dose adjustments based on clinical assessment. Ribociclib is a moderate CYP3A4 inhibitor and buspirone is a CYP3A4 substrate.
Butabarbital: (Moderate) Use caution if coadministration of ribociclib with butabarbital is necessary, as the systemic exposure of ribociclib may be decreased resulting in decreased efficacy. Ribociclib is extensively metabolized by CYP3A4 and butabarbital is a CYP3A4 inducer.
Cabozantinib: (Moderate) Use caution if coadministration of ribociclib with cabozantinib is necessary, as the systemic exposure of cabozantinib may be increased resulting in an increase in cabozantinib-related adverse reactions. Ribociclib is a moderate CYP3A4 inhibitor and cabozantinib is a CYP3A4 substrate.
Caffeine; Ergotamine: (Major) Use caution if coadministration of ribociclib, a moderate CYP3A4 inhibitor, with ergotamine, a CYP3A4 substrate, is necessary, as the systemic exposure of ergotamine may be increased resulting in an increase in ergotamine-related adverse reactions including the risk for vasospasm leading to cerebral ischemia and/or ischemia of the extremities; adjust the dose of ergotamine if necessary.
Carbamazepine: (Major) Avoid coadministration of ribociclib with carbamazepine, as the systemic exposure of ribociclib may be decreased resulting in decreased efficacy; consider an alternative treatment with less potential to induce CYP3A. Additionally, carbamazepine exposure may be increased resulting in an increase in carbamazepine-related adverse reactions. Ribociclib is extensively metabolized by CYP3A4 and is a moderate CYP3A4 inhibitor; carbamazepine is a strong CYP3A4 inducer and a CYP3A4 substrate.
Carbinoxamine; Dextromethorphan; Pseudoephedrine: (Moderate) Use caution if coadministration of ribociclib with dextromethorphan is necessary, as the systemic exposure of dextromethorphan may be increased resulting in increase in treatment-related adverse reactions. Ribociclib is a moderate CYP3A4 inhibitor and dextromethorphan is a CYP3A4 substrate.
Carbinoxamine; Hydrocodone; Phenylephrine: (Moderate) Use caution if coadministration of ribociclib with hydrocodone is necessary, as the systemic exposure of hydrocodone may be increased resulting in an increase in treatment-related adverse reactions including sedation and respiratory depression; adjust the dose of hydrocodone if necessary. Ribociclib is a moderate CYP3A4 inhibitor and hydrocodone is a CYP3A4 substrate.
Carbinoxamine; Hydrocodone; Pseudoephedrine: (Moderate) Use caution if coadministration of ribociclib with hydrocodone is necessary, as the systemic exposure of hydrocodone may be increased resulting in an increase in treatment-related adverse reactions including sedation and respiratory depression; adjust the dose of hydrocodone if necessary. Ribociclib is a moderate CYP3A4 inhibitor and hydrocodone is a CYP3A4 substrate.
Cariprazine: (Moderate) Use caution if coadministration of ribociclib with cariprazine is necessary, as the systemic exposure of cariprazine may be increased resulting in an increase in treatment-related adverse reactions. Ribocicli |
